The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
This study was designed to determine the effects of vandetanib, a small-molecule receptor tyrosine kinase inhibitor of vascular endothelial growth factor and epidermal growth factor receptor, on paclitaxel (PTX) tumor distribution and antitumor activity in xenograft models of human ovarian carcinoma...
Auteurs principaux: | Cesca, M, Frapolli, R, Berndt, A, Scarlato, V, Richter, P, Kosmehl, H, D'Incalci, M, Ryan, A, Giavazzi, R |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
2009
|
Documents similaires
-
The Effects of Vandetanib on Paclitaxel Tumor Distribution and Antitumor Activity in a Xenograft Model of Human Ovarian Carcinoma
par: Marta Cesca, et autres
Publié: (2009-11-01) -
Hyaluronic Acid- Paclitaxel: Antitumor Efficacy against CD44(+) Human Ovarian Carcinoma Xenografts
par: Edmond Auzenne, et autres
Publié: (2007-06-01) -
Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.
par: Wachsberger, P, et autres
Publié: (2009) -
Determination of paclitaxel distribution in solid tumors by nano-particle assisted laser desorption ionization mass spectrometry imaging.
par: Lavinia Morosi, et autres
Publié: (2013-01-01) -
Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model.
par: Choi, S, et autres
Publié: (2008)